



Fig. S1: A workflow for sgRNA/Cas9 RNP injection into *Xenopus tropicalis*

We established an efficient and rapid gene disruption workflow for the loss-of-function analysis using the CRISPR-Cas system in *X. tropicalis* founders. First, we design one or more sgRNAs targeting 5' exons or exon-intron junctions to induce frameshift mutations and/or splicing errors. Next, sgRNAs are synthesized *in vitro* by T7 RNA polymerase using templates produced by PCR and assembled with Cas9 protein to form an RNP complex. sgRNA/Cas9 RNP is injected into one-cell-stage fertilized eggs, and the developing embryos (crispants) are genotyped by HMA and amplicon-sequencing followed by phenotyping.


A




B



C



D



E

target gene (total crispant samples)	<i>tyr</i> (n = 10)	<i>oca2</i> (n = 5)
wild-type reads (%)	0 (0 %)	0 (0 %)
mutant reads (%)	24936 (100 %)	13309 (100 %)
total reads	24936	13309

Fig. S2: Phenotyping and genotyping of embryos with disrupted melanin synthesis-related genes

(A) Schematic illustration of the gene structure and sgRNA targeting sequences of *tyrosinase* (*tyr*) and *oculocutaneous albinism 2* (*oca2*) genes. Coding regions are shown as black boxes. Sequences highlighted in red and gray denote protospacer adjacent motif (PAM) and the 20 bp target sequence of sgRNA, respectively. Capital letters: exon; small letters: intron. (B) Representative severe phenotypes of *tyr* and *oca2* crispants. (C) Phenotypes were classified into four groups: severe, near complete loss of pigmentation in retinal pigmented epithelium; moderate, more than half of pigmentation lost; weak, less than half of pigmentation lost; and normal, no alteration in pigmentation (Shigeta et al., 2016; Sakane et al., 2017). (D) Genotyping of crispants with HMA. Target regions were amplified with 35 cycles of PCR. Genomic PCR products were analyzed using microchip electrophoresis. Arrowheads and brackets indicate homoduplex and heteroduplex bands, respectively. Ui: uninjected control embryos. (E) The numbers and percentages of wild-type and mutant allele reads in each crispant. Reads obtained from next-generation sequencing were classified into each gene and individual by their specific barcode sequences. According to sequence data from uninjected control embryos, the rates of artificial backgrounds such as PCR or sequencing errors were calculated, and we discounted reads below these artificial background rates. Significant reads in ten *tyr* and five *oca2* crispants were counted as total reads and somatic mutation rates were calculated.




Fig. S3: mRNA expression of *trβ* in the absent of T3

The result of *trβ* expression in control and crispants without T3. The scale of Y axis is enlarged in Fig. 4. *, $P < 0.005$; Welch's *t*-test.




Fig. S4: Histological analysis of intestine

Intestines of uninjected control froglets and *trβ* crispants about one month after metamorphosis were processed for histology and stained with hematoxylin and eosin. Intestinal folds (IF), which develop only in the adult organ, were observed in both control froglets and crispants. Bar: 50 μ m.




Fig. S5: Tentacle resorption was delayed in *trβ* crispants

About one week after metamorphosis, tentacles remained near the mouth of *trβ* crispants (arrowheads). Images are representative of six uninjected control froglets and eleven *trβ* crispants. The number of froglets with remaining tentacle(s) is given in the images.

Supplementary information table**Table S1: Sequences of sgRNA targeting sites.**

sgRNA name	Target sites (5' to 3')
<i>tyr</i>	<u>CCAT</u> GTTTGCAGGGGCCAGTTCC
<i>oca2</i>	<u>CCT</u> GGGTGAGTTCAGCTTTCTGT
<i>trβ-1</i>	GATGAGCTATGCGTGGTGTG <u>TGG</u>
<i>trβ-2</i>	AGGGCTGCAAGGTAACAGAT <u>TGG</u>

PAM sequence is underlined.

Table S2: Oligonucleotide information in this study.

Primers used for HMA.

Target gene	Forward primer sequence (5' to 3')	Reverse primer sequence (5' to 3')
<i>tyr</i>	AAGCCTGCACATGTGATTGTGCTT G	GAGGACCCATCTCCAGACCACAC AG
<i>oca2</i>	TGTTTGTCTGTCTTGGGCTTTGTC A	GGGTTACAGCACTGATATGACT ATGG
<i>trβ</i>	TTTCTTTCTTTGCTTTCCTTATCA	ACTGCTGTAGCGCAGGGTTC

Oligonucleotides used for PCR assembly for sgRNA template.

sgRNA name	Forward oligonucleotide sequence (5' to 3')
<i>oca2</i>	TAATACGACTCACTATAGGAGAAAGCTGAACTCACCCGTTTTAGAGCT AGAAATAGCAAG
<i>trβ-1</i>	TAATACGACTCACTATAGGTGAGCTATGCGTGGTGTGGTTTTAGAGCT AGAAATAGCAAG
<i>trβ-2</i>	TAATACGACTCACTATAGGGGCTGCAAGGTAACAGATGTTTTAGAGC TAGAAATAGCAAG

Reverse oligonucleotide sequence (5' to 3')	AAAAGCACCGACTCGGTGCCACTTTTTCAAGTTGATAACGG ACTAGCCTTATTTAACTTGCTATTTCTAGCTCTAAAAC
--	---

Oligonucleotides used for constructing sgRNA vector.

sgRNA name	Sequence (5' to 3')	
<i>tyr</i>	Sense	TATAGGAACTGGCCCCTGCAAACAG
	Antisense	AAAAGTGTTCAGGGGCCAGTTCC

Primers for sgRNA *in vitro* transcription template.

Primer name	Sequence (5' to 3')
IVT-gRNA-F	GAATTCTAATACGACTCAC
IVT-gRNA-R	AAAAGCACCGACTCGG

Primers for the amplicon sequence.

The overhang adapter and barcode sequences are added to the locus-specific primer. Barcode sequences are indicated by small letters.

Primer name	Sequence (5' to 3')
<i>tyr</i> -Wt-ampliconseq1-F	TCGTCGGCAGCGTCAGATGTGTATAAGAGACAGttaaAGCAGCATG GAAAGGAACATG
<i>tyr</i> -Wt-ampliconseq1-R	GTCTCGTGGGCTCGGAGATGTGTATAAGAGACAGttaaCAGAGCTG GTCAGGACAACATC
<i>tyr</i> -Wt-ampliconseq2-F	TCGTCGGCAGCGTCAGATGTGTATAAGAGACAGaaccgAGCAGCAT GGAAAGGAACATG
<i>tyr</i> -Wt-ampliconseq2-R	GTCTCGTGGGCTCGGAGATGTGTATAAGAGACAGatcgCAGAGCTG GTCAGGACAACATC
<i>tyr</i> -Wt-ampliconseq3-F	TCGTCGGCAGCGTCAGATGTGTATAAGAGACAGagcgAGCAGCAT GGAAAGGAACATG
<i>tyr</i> -Wt-ampliconseq3-R	GTCTCGTGGGCTCGGAGATGTGTATAAGAGACAGaccgCAGAGCT GGTCAGGACAACATC
<i>tyr</i> -Wt-ampliconseq4-F	TCGTCGGCAGCGTCAGATGTGTATAAGAGACAGacgAGCAGCATG GAAAGGAACATG
<i>tyr</i> -Wt-ampliconseq4-R	GTCTCGTGGGCTCGGAGATGTGTATAAGAGACAGgtagCAGAGCTG GTCAGGACAACATC

tyr-Wt- ampliconseq5-F	TCGTCGGCAGCGTCAGATGTGTATAAGAGACAGcacgAGCAGCAT GGAAAGGAACATG
tyr-Wt- ampliconseq5-R	GTCTCGTGGGCTCGGAGATGTGTATAAGAGACAGtatgCAGAGCTG GTCAGGACAACATC
oca2-Wt- ampliconseq1-F	TCGTCGGCAGCGTCAGATGTGTATAAGAGACAGcaatATGTTTGTC TGTCTTGGGCTTT
oca2-Wt- ampliconseq1-R	GTCTCGTGGGCTCGGAGATGTGTATAAGAGACAGctatAAGGGGTT ACAGCACTGATATG
oca2-Wt- ampliconseq2-F	TCGTCGGCAGCGTCAGATGTGTATAAGAGACAGcacacATGTTTGTC TGTCTTGGGCTTT
oca2-Wt- ampliconseq2-R	GTCTCGTGGGCTCGGAGATGTGTATAAGAGACAGgactAAGGGGTT ACAGCACTGATATG
oca2-Wt- ampliconseq3-F	TCGTCGGCAGCGTCAGATGTGTATAAGAGACAGttacATGTTTGTCT GTCTTGGGCTTT
oca2-Wt- ampliconseq3-R	GTCTCGTGGGCTCGGAGATGTGTATAAGAGACAGtgacAAGGGGTT ACAGCACTGATATG
oca2-Wt- ampliconseq4-F	TCGTCGGCAGCGTCAGATGTGTATAAGAGACAGaatgATGTTTGTC TGTCTTGGGCTTT
oca2-Wt- ampliconseq4-R	GTCTCGTGGGCTCGGAGATGTGTATAAGAGACAGtgcaAAGGGGTT ACAGCACTGATATG
oca2-Wt- ampliconseq5-F	TCGTCGGCAGCGTCAGATGTGTATAAGAGACAGgtacATGTTTGTC TGTCTTGGGCTTT
oca2-Wt- ampliconseq5-R	GTCTCGTGGGCTCGGAGATGTGTATAAGAGACAGggacAAGGGGT TACAGCACTGATATG

Primer name	Sequence (5' to 3')
tyr-Mt- ampliconseq1-F	TCGTCGGCAGCGTCAGATGTGTATAAGAGACAGttaagAGCAGCATG GAAAGGAACATG
tyr-Mt- ampliconseq1-R	GTCTCGTGGGCTCGGAGATGTGTATAAGAGACAGttaagCAGAGCTG GTCAGGACAACATC
tyr-Mt- ampliconseq2-F	TCGTCGGCAGCGTCAGATGTGTATAAGAGACAGaacgAGCAGCAT GGAAAGGAACATG

tyr-Mt-ampliconseq2-R	GTCTCGTGGGCTCGGAGATGTGTATAAGAGACAGatcgCAGAGCTG GTCAGGACAACATC
tyr-Mt-ampliconseq3-F	TCGTCGGCAGCGTCAGATGTGTATAAGAGACAGagcgAGCAGCAT GGAAAGGAACATG
tyr-Mt-ampliconseq3-R	GTCTCGTGGGCTCGGAGATGTGTATAAGAGACAGaccgCAGAGCT GGTCAGGACAACATC
tyr-Mt-ampliconseq4-F	TCGTCGGCAGCGTCAGATGTGTATAAGAGACAGacgAGCAGCATG GAAAGGAACATG
tyr-Mt-ampliconseq4-R	GTCTCGTGGGCTCGGAGATGTGTATAAGAGACAGgtagCAGAGCTG GTCAGGACAACATC
tyr-Mt-ampliconseq5-F	TCGTCGGCAGCGTCAGATGTGTATAAGAGACAGcagAGCAGCAT GGAAAGGAACATG
tyr-Mt-ampliconseq5-R	GTCTCGTGGGCTCGGAGATGTGTATAAGAGACAGtatgCAGAGCTG GTCAGGACAACATC
tyr-Mt-ampliconseq6-F	TCGTCGGCAGCGTCAGATGTGTATAAGAGACAGttcgAGCAGCATG GAAAGGAACATG
tyr-Mt-ampliconseq6-R	GTCTCGTGGGCTCGGAGATGTGTATAAGAGACAGtccgCAGAGCTG GTCAGGACAACATC
tyr-Mt-ampliconseq7-F	TCGTCGGCAGCGTCAGATGTGTATAAGAGACAGtgcgAGCAGCATG GAAAGGAACATG
tyr-Mt-ampliconseq7-R	GTCTCGTGGGCTCGGAGATGTGTATAAGAGACAGggttCAGAGCTG GTCAGGACAACATC
tyr-Mt-ampliconseq8-F	TCGTCGGCAGCGTCAGATGTGTATAAGAGACAGctcgAGCAGCATG GAAAGGAACATG
tyr-Mt-ampliconseq8-R	GTCTCGTGGGCTCGGAGATGTGTATAAGAGACAGcccgCAGAGCT GGTCAGGACAACATC
tyr-Mt-ampliconseq9-F	TCGTCGGCAGCGTCAGATGTGTATAAGAGACAGcgcgAGCAGCAT GGAAAGGAACATG
tyr-Mt-ampliconseq9-R	GTCTCGTGGGCTCGGAGATGTGTATAAGAGACAGgacgCAGAGCT GGTCAGGACAACATC
tyr-Mt-ampliconseq10-F	TCGTCGGCAGCGTCAGATGTGTATAAGAGACAGgtcgAGCAGCATG GAAAGGAACATG

tyr-Mt- ampliconseq10-R	GTCTCGTGGGCTCGGAGATGTGTATAAGAGACAGgccgCAGAGCT GGTCAGGACAACATC
oca2-Mt- ampliconseq1-F	TCGTCGGCAGCGTCAGATGTGTATAAGAGACAGcaatATGTTTGTC TGTCTTGGGCTTT
oca2-Mt- ampliconseq1-R	GTCTCGTGGGCTCGGAGATGTGTATAAGAGACAGctatAAGGGGTT ACAGCACTGATATG
oca2-Mt- ampliconseq2-F	TCGTCGGCAGCGTCAGATGTGTATAAGAGACAGacacATGTTTGTC TGTCTTGGGCTTT
oca2-Mt- ampliconseq2-R	GTCTCGTGGGCTCGGAGATGTGTATAAGAGACAGgactAAGGGGTT ACAGCACTGATATG
oca2-Mt- ampliconseq3-F	TCGTCGGCAGCGTCAGATGTGTATAAGAGACAGttacATGTTTGTC GTCTTGGGCTTT
oca2-Mt- ampliconseq3-R	GTCTCGTGGGCTCGGAGATGTGTATAAGAGACAGtgacAAGGGGTT ACAGCACTGATATG
oca2-Mt- ampliconseq4-F	TCGTCGGCAGCGTCAGATGTGTATAAGAGACAGaatgATGTTTGTC TGTCTTGGGCTTT
oca2-Mt- ampliconseq4-R	GTCTCGTGGGCTCGGAGATGTGTATAAGAGACAGtgcaAAGGGGTT ACAGCACTGATATG
oca2-Mt- ampliconseq5-F	TCGTCGGCAGCGTCAGATGTGTATAAGAGACAGgtacATGTTTGTC TGTCTTGGGCTTT
oca2-Mt- ampliconseq5-R	GTCTCGTGGGCTCGGAGATGTGTATAAGAGACAGggacAAGGGGT TACAGCACTGATATG

Primer name	Sequence (5' to 3')
tr β -Mt- ampliconseq1-F	TCGTCGGCAGCGTCAGATGTGTATAAGAGACAGacgGGTATCAAAG GGTGTCCAAAAA
tr β -Mt- ampliconseq1-R	GTCTCGTGGGCTCGGAGATGTGTATAAGAGACAGgtagATTTCCAG GCAGTGCCAATA
tr β -Mt- ampliconseq2-F	TCGTCGGCAGCGTCAGATGTGTATAAGAGACAGcacgGGTATCAAA GGGTGTCCAAAAA
tr β -Mt- ampliconseq2-R	GTCTCGTGGGCTCGGAGATGTGTATAAGAGACAGtatgATTTCCAGG CAGTGCCAATA

tr β -Mt- ampliconseq3-F	TCGTCGGCAGCGTCAGATGTGTATAAGAGACAGttcgGGTATCAAA GGGTGTCCAAAAA
tr β -Mt- ampliconseq3-R	GTCTCGTGGGCTCGGAGATGTGTATAAGAGACAGtccgATTTCCAGG CAGTGCCAATA
tr β -Mt- ampliconseq4-F	TCGTCGGCAGCGTCAGATGTGTATAAGAGACAGtgcgGGTATCAAA GGGTGTCCAAAAA
tr β -Mt- ampliconseq4-R	GTCTCGTGGGCTCGGAGATGTGTATAAGAGACAGggttATTTCCAGG CAGTGCCAATA
tr β -Mt- ampliconseq5-F	TCGTCGGCAGCGTCAGATGTGTATAAGAGACAGctcgGGTATCAAA GGGTGTCCAAAAA
tr β -Mt- ampliconseq5-R	GTCTCGTGGGCTCGGAGATGTGTATAAGAGACAGcccgATTTCCAG GCAGTGCCAATA
tr β -Mt- ampliconseq6-F	TCGTCGGCAGCGTCAGATGTGTATAAGAGACAGcgcgGGTATCAAA GGGTGTCCAAAAA
tr β -Mt- ampliconseq6-R	GTCTCGTGGGCTCGGAGATGTGTATAAGAGACAGgacgATTTCCAG GCAGTGCCAATA
tr β -Mt- ampliconseq7-F	TCGTCGGCAGCGTCAGATGTGTATAAGAGACAGgtcgGGTATCAAA GGGTGTCCAAAAA
tr β -Mt- ampliconseq7-R	GTCTCGTGGGCTCGGAGATGTGTATAAGAGACAGgccgATTTCCAG GCAGTGCCAATA
tr β -Mt- ampliconseq8-F	TCGTCGGCAGCGTCAGATGTGTATAAGAGACAGcaatGGTATCAAA GGGTGTCCAAAAA
tr β -Mt- ampliconseq8-R	GTCTCGTGGGCTCGGAGATGTGTATAAGAGACAGctatATTTCCAGG CAGTGCCAATA

Primers used for RT-PCR.

Target gene	Forward primer sequence (5' to 3')	Reverse primer sequence (5' to 3')
<i>trβ</i>	AAGAAACAAAACCTGGCCATC	AAGCGACATTCTTGCCACT

Primers used for qPCR

Target gene	Forward primer sequence (5' to 3')	Reverse primer sequence (5' to 3')

<i>rpl8</i>	CCCTCAACCATCAGGAGAGA	TCTTTGTACCACGCAGACGA
<i>trβ</i>	ATAATGCCAAGCAGTATGTCAGA GA	CACACACCACGCATAGCTCAT
<i>klf9</i>	GGTGCCTTATGCTGGGTGT	GCGAGTCAACTCATCGGAAC
<i>fra-2</i>	TCCCATCCTTACAGCCACTC	TTCTCCTGCTCCAGCTTCTC
<i>mmp13</i>	CCGAGGGTTACTTGGACAAA	CACCGACATCCCAAAGAACT
<i>fapa</i>	ATCCTGGGGAAAAGCCTCTA	CTGGGGCCTCTTCATATTCA